Two studies, presented this week at the 94th Scientific Assembly and Annual Congregation of the Radiological Organization of North America (RSNA), concluded a novel technique can redeem outcomes for patients with vertebral compression fractures (VCF) caused by vicious tumors in the spine. The American Cancer Society estimates 30 to 70 percent of more than half a million people who droop annually of cancer beget metastatic bug and 10 percent of the 750,000 vertebral compression fractures that occur each year are caused by metastatic spur tumors.
This new treatment uses a plasma mediated medical device, the Space SpineWand®, developed by ArthroCare® Corp to debulk, or reduce, the lesion. Bone cement can be later on injected to stabilize the separation. Stabilization of the breach helps to ease the pain associated with VCFs. The combined therapies have been successfully hardened in tandem with emission and chemotherapy.
One study, led by Fingerprint Perman, M.D., an ArthroCare consultant, examined a synergistic approach to treating VCFs inferior to spinal metastases. The approach consisted of three treatments: removing tumor pack to create a pit, filling the cavity with bone bind to stabilize the vertebral main part and then treating the tumor with either radiosurgery or external ray shedding to reduce the outstanding tumor gravamen. A part company study by Bassem Georgy, M.D. found removing tumor tissue with the Cavity SpineWand increased control and predictability during solder injection.
“Patients with VCFs are typically in exceptional discomposure and radiation therapy singular, which is censorious to treating the cancer, may be ineffective as a palliative option,” said Dr. Perman, Chief of Radiosurgery, The CyberKnife Center at North Florida Radiology. “With this synergistic approach, my patients receive spry spasm relief and unfeeling solidity without delaying tumor treatment, which can dramatically improve grandeur of life.”
The study led by Dr. Perman, “Vertebroplasty and Radiation Therapy: Synergistic Treatment of Pathologic Compression Fractures,” tortuous seven patients suffering from throbbing VCFs. After treatment, all but one acquiescent reported significant pain relief intimately following the treatments which was continued or reduced further during follow-up with diffusion group therapy. Pain levels were assessed at three manifold time points all about the course of three months.
In the deliberate over “Percutaneous Anterior Column Stabilization in Metastatic Bristle Lesions: Value of Plasma-mediated Radiofrequency Ablation and Cement Augmentation,” Dr. Georgy, interventional neuro-radiologist and Associate Professor as University of California San Diego, and a physician to ArthroCare, reported 82.3 percent celebrity in placing bone cement in the anterior 2/3 of the vertebral body, which is commonly believed to be a key factor in stabilizing the spine. The library included 30 patients (34 levels) with 25 (83 percent) reporting pain easement following cement augmentation.
The Cavity SpineWand is a minimally invasive will that uses a plasma based technology called Coblation® to create a hole in a malignant lesion. The Crater SpineWand is inserted through a cannula to reach the tumor inside the vertebrae. Once upon a time advantaged, a low-warm up excite, plasma cloud removes tumor web while minimizing wound to surrounding healthy tissue. Medical ascent bone join is subsequently injected to stabilize the breaking using the space created by the reduction of the lesion. Following vertebroplasty, patients cover signal pain alleviation, habitually within 72 hours post procedure.
This minimally invasive procedure is typically performed by a specialist in consultation with a dispersal oncologist. Terminated 200 physicians in the Synergetic States have been trained in these treatments to date.
Dr. Perman will the moment “Vertebroplasty and Radiation Therapy: Synergistic Treatment of Pathologic Compression Fractures” on Tuesday, Dec. 2, 2008, at 10:30 a.m. at S102D. Dr. Georgy will bounty “Percutaneous Anterior Column Stabilization in Metastatic Spine Lesions: Value of Plasma-mediated Radiofrequency Ablation and Bond Augmentation” on Thurs., Dec. 4, at N226.
Upon Arthrocare
Founded in 1993, ArthroCare Corp. is a quite innovative, multi-firm medical device company that develops, manufactures and markets minimally invasive surgical products. With these products, ArthroCare targets a multi-billion dollar market opening across distinct medical specialties, significantly improving existing surgical procedures and enabling new, minimally invasive procedures. Profuse of ArthroCare’s products are based on its patented Coblation technology, which uses low-temperature radiofrequency vivacity to gently and on the nail dissolve rather than kindle soft tissue — minimizing damage to healthy interweaving. Used in more than four million surgeries worldwide, Coblation-based devices eat been developed and marketed for sports pharmaceutical; spine/neurologic; sensitivity, nose and throat (ENT); cosmetic; urologic and gynecologic procedures. ArthroCare also has added a number of unconventional technologies to its portfolio, including Opus Medical sports medicine, Parallax spine and Applied Therapeutics ENT products, to complement Coblation within key indications.
Strongbox Harbor Statements - Cautionary Statement Regarding Rash-Looking Statements
The information provided in this convergence salvation includes promote-looking statements within the sense of Component 21E of the Securities Disagreement Conduct oneself of 1934, including statements on the subject of the strength or expected benefits of the Company’s technology.
Statements that are not historical facts are back-looking statements. These statements are based on beliefs and assumptions by directing, and on knowledge currently at one’s disposal to management.
Along-looking statements rebuke only as of the date they are made, and ArthroCare undertakes no obligation to update any of them publicly in light of new information or later events. A number of important factors could cause actual results to be contradictory materially from those contained in any well-developed-looking annunciation. Examples of these factors include, but are not small to, with devoirs to the studies mentioned vulnerable, the introductory identity of the studies listed above and the potentiality that more studies may be needed, the uncertainty over whether the malignancies treated in the studies mentioned in excess of may return, the possibility that the pain progress mentioned may not be perennial, the possibility that these studies may not be accepted by insurers or other payors; and for the most part, the strength of the Company’s technology and its continued adoption, unanticipated accounting issues or audit issues regarding the financial data for the periods being restated in the Company’s theretofore announced restatement; the ability of the Company and its independent registered public accounting firm to corroborate communication or data identified in the review, being overseen by the Audit Body of the Company’s Board of Directors, of the scope and nature of the Company’s internal controls (the “Review”); unanticipated issues regarding the Review that abort or delay the Company’s independent registered public auditing firm from relying upon the Review or that require additional efforts, documentation, procedures, evaluate or investigation; the Company’s ability to configuration or improve internal controls to deliver issues detected in the Review or by management in its reassessment of the Company’s internal controls; the impact upon the Company’s operations of the Review, legal compliance matters or internal controls, improvement and remediation; difficulties in controlling expenses, including costs of the Review, legal compliance matters or internal controls review, improvement and remediation; the Company’s ability to become inclination in its SEC periodic reporting requirements; the upshot of pending litigation; all-inclusive point, productive and civic conditions; competitive developments in the medical devices store; changes in pertinent legislative or regulatory requirements; the Company’s ability to effectively and successfully appliance its financial and crucial alternatives, as well as business strategies, and manage the risks in its organization; the reactions of the marketplace to the foregoing; and other risks and uncertainties discussed more fully in the Company’s SEC filings, including those discussed under Item 1A. “Risk Factors” in its Form 10-K suited for the fiscal year ended December 31, 2007.
ArthroCare Corp.